Page 1363 - Williams Hematology ( PDFDrive )

1338 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1339

406. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary 438. Centanara E, Guarone R, Ippoliti G, Barosi G: Cyclosporine-A in severe refractory
myelofibrosis based on a study of the International Working Group for Myelofibrosis anemia of myelofibrosis with myeloid metaplasia: A preliminary report. Haematologica
Research and Treatment. Blood 113:2895, 2009. 83:622, 1998.
407. Barois G, Liberato LN, Guarnone R: Serum erythropoietin in patients with myeloid 439. Nemoto Y, Tsutani H, Imamura S, et al: Successful treatment of acquired myelofibrosis
metaplasia. Br J Haematol 83:365, 1993. with pure red cell aplasia. Br J Haematol 104:420, 1999.
408. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al: Erythropoietin treatment 440. Tsimberidou AM, Giles FJ: TNF-α targeted therapeutic approaches in patients with
of the anaemia of myelofibrosis with myeloid metaplasia: Results in 20 patients and hematologic malignancies. Expert Rev Anticancer Ther 2:277, 2002.
review of the literature. Br J Haematol 127:399, 2004. 441. Steensma DP, Mesa RA, Li CY, et al: Etanercept, a soluble tumor necrosis factor recep-
409. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al: Darbepoetin-alpha for the tor, palliates constitutional symptoms in patients with myelofibrosis with myeloid
anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134:184, 2006. metaplasia: Results of a pilot study. Blood 99:2252, 2002.
410. Cervantes F, Alvarez-Larrán A, Domingo A, et al: Efficacy and tolerability of danazol 442. Mesa RA: The therapy of myelofibrosis: Targeting pathogenesis. Int J Hematol 76 Suppl
as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term 2:296, 2002.
results in 30 patients. Br J Haematol 129:771, 2005. 443. Tefferi A, Mesa RA, Gray LA, et al: Phase 2 trial of imatinib mesylate in myelofibrosis
411. Makdisi WJ, Cherian R, Vanveldhuizen PJ, et al: Fatal peliosis of the liver and spleen in with myeloid metaplasia. Blood 99:3854, 2002.
a patient with agnogenic myeloid metaplasia treated with danazol. Am J Gastroenterol 444. Mesa RA, Camoriano JK, Geyer SM, et al: A phase II trial of tipifarnib in myelofibro-
90:317, 1995. sis: Primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia
412. Ozsoylu S, Ruacan S: High-dose intravenous corticosteroid treatment in childhood 21:1964, 2007.
idiopathic myelofibrosis. Acta Haematol 75:49, 1986. 445. Carlo-Stella C, Cazzola M, Gasner A, et al: Effects of recombinant alpha and gamma
413. Cetingül N, Yener E, Oztop S, et al: Agnogenic myeloid metaplasia in childhood: A interferons on the in vitro growth of circulating hematopoietic progenitors from
report of two cases and efficiency of intravenous high dose methylprednisolone treat- patients with myelofibrosis and myeloid metaplasia. Blood 70:1014, 1987.
ment. Acta Paediatr Jpn 36:697, 1994. 446. Sacchi S: The role of alpha-interferon in essential thrombocythaemia, polycythaemia
414. Wilks AF: The JAK kinases: Not just another kinase drug discovery target. Semin Cell vera and myelofibrosis with myeloid metaplasia (MMM): A concise update. Leuk
Dev Biol 19:319, 2008. Lymphoma 19:13, 1995.
415. Pardanani A, Hood J, Lasho T, et al: TG101209, a small molecule JAK2-selective kinase 447. Bachleitner-Hofmann T, Gisslinger H: The role of interferon-alpha in the treatment of
inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and idiopathic myelofibrosis. Ann Hematol 78:533, 1999.
MPLW515L/K mutations. Leukemia 21:1658, 2007. 448. Heis-Vahidi-Fard N, Forberg E, Eichinger S, et al: Ineffectiveness of interferon-gamma
416. Verstovsek S, Kantarjian HM, Pardanani AD, et al: The JAK inhibitor, INCB018424, in the treatment of idiopathic myelofibrosis: A pilot study. Ann Hematol 80:79, 2001.
demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) 449. Gowin K, Thapaliya P, Samuelson J, et al: Experience with pegylated interferon α-2a
and post-polycythemia/essential thrombocythemia myelofibrosis (PV/ET-MF). Blood in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
112:622, 2008. Haematologica 97:1570, 2012.
417. Pardanani AD, Gotlib J, Jamieson C, et al: A phase I study of TG101348, an orally 450. Ianotto JC, Boyer-Perrard F, Gyan E, et al: Efficacy and safety of pegylated-interferon
bioavailable JAK-2 selective inhibitor, in patients with myelofibrosis. Blood 112:43, α-2a in myelofibrosis: A study by the FIM and GEM French cooperative groups. Br J
2008. Haematol 162:783, 2013.
418. Shah, NP, Olszynski P, Sokol, L, et al: A phase I study of XL019, a selective JAK2 inhibi- 451. Silver RT, Vandris K, Goldman JJ: Recombinant interferon-α may retard progression of
tor, in patients with primary myelofibrosis polycythemia vera, or post-essential throm- early primary myelofibrosis: A preliminary report. Blood 117:6669, 2011.
bocythemia myelofibrosis. Blood 112:441, 2008. 452. Stahl RL, Hoppstein L, Davidson TG: Intraperitoneal chemotherapy with cytosine ara-
419. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best binoside in agnogenic myelofibrosis with myeloid metaplasia and ascites due to perito-
available therapy for myelofibrosis. N Engl J Med 366:787, 2012. neal extramedullary hematopoiesis. Am J Hematol 43:156, 1993.
420. Verstovsek S, Mesa RA, Gotlib J, et al: The clinical benefit of ruxolitinib across patient 453. Camba L, Aldrighetti L, Ciceri F, et al: Locoregional intrasplenic chemotherapy for
subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofi- hypersplenism in myelofibrosis. Br J Haematol 114:638, 2001.
brosis. Br J Haematol 161:508, 2013. 454. Amital H, Rewald E, Levy Y, et al: Fibrosis regression induced by intravenous gamma-
421. Mesa RA, Gotlib J, Gupta V, et al: Effect of ruxolitinib therapy on myelofibrosis- globulin treatment. Ann Rheum Dis 62:175, 2003.
related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, 455. Sivera P, Cesano L, Guerrasio A, et al: Clinical and hematological improvement induced
double-blind, placebo-controlled trial. J Clin Oncol 31:1285, 2013. by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. Br J Haematol
422. Mesa RA, Kiladjian JJ, Verstovsek S, et al: Comparison of placebo and best available ther- 86:397, 1994.
apy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 456. Froom P, Elmalah I, Braester A, et al: Clodronate in myelofibrosis: A case report. Am J
99:292, 2014. Med Sci 323:115, 2002.
423. Talpaz M, Paquette R, Afrin L, et al: Interim analysis of safety and efficacy of ruxolitinib 457. Assous N, Foltz V, Fautrel B, et al: Bone involvement in myelofibrosis: Effectiveness of
in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6:81, 2013. bisphosphonates. Joint Bone Spine 72:591, 2005.
424. Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocy- 458. Elliott MA, Tefferi A: Splenic irradiation in myelofibrosis with myeloid metaplasia: A
thaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375, 1988. review. Blood Rev 13:163, 1999.
425. Lofvenberg E, Wahlin A, Roos G, Ost A: Reversal of myelofibrosis by hydroxyurea. Eur 459. Jacobs P, Wood L, Robson S: Refractory ascites in the chronic myeloproliferative syn-
J Haematol 44:33, 1990. drome. Am J Hematol 37:128, 1991.
426. Manoharan A: Management of myelofibrosis with intermittent hydroxyurea. Br J 460. Jacobs P, Sellars S: Granulocytic sarcoma preceding leukaemic transformation in myel-
Haematol 71:252, 1991. ofibrosis. Postgrad Med J 61:1069, 1985.
427. Petti MC, Latagliata R, Spadea T, et al: Melphalan treatment in patients with myelofi- 461. Teffari A, Jimenez T, Gray LA, et al: Radiation therapy for symptomatic hepatomegaly
brosis with myeloid metaplasia. Br J Haematol 116:576, 2002. in myelofibrosis with myeloid metaplasia. Eur J Haematol 66:37, 2001.
428. Tefferi A: Polycythemia vera and essential thrombocythemia: 2013 Update on diagno- 462. Mesa RA, Nagorney DS, Schwager S, et al: Palliative goals, patient selection, and periop-
sis, risk-stratification, and management. Am J Hematol 88:507, 2013. erative platelet management: Outcomes and lessons from 3 decades of splenectomy for
429. Merup M, Kutti J, Birgerård G, et al: Negligible clinical effects of thalidomide in patient myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107:361, 2006.
with myelofibrosis with myeloid metaplasia. Med Oncol 19:79, 2002. 463. Tefferi A, Barrett SM, Silverstein NM, Nagorney DM: Outcome of portal-systemic
430. Piccaluga PP, Visani G, Pileri SA, et al: Clinical efficacy and antiangiogenic activity of shunt surgery for portal hypertension associated with intrahepatic obstruction in
thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 16:1609, patients with agnogenic myeloid metaplasia. Am J Hematol 46:325, 1994.
2002. 464. Angermayr B, Cejna M, Schoder M, et al: Transjugular intrahepatic portosystemic
431. Strupp C, Germing U, Scherer A, et al: Thalidomide for treatment of idiopathic myelo- shunt for treatment of portal hypertension due to extramedullary hematopoiesis in
fibrosis. Eur J Haematol 72:52, 2004. idiopathic myelofibrosis. Blood 99:4246, 2002.
432. Mesa RA, Lliott MA, Schroeder G, Tefferi A: Durable responses to thalidomide-based 465. Belohlavek J, Schwarz J, Jirásek A, et al: Idiopathic myelofibrosis complicated by por-
drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 79:883, 2004. tal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS).
433. Tefferi A, Cortes J, Verstovsek S, et al: Lenalidomide therapy in myelofibrosis with mye- Wien Klin Wochenschr 113:208, 2001.
loid metaplasia. Blood 108:1158, 2006. 466. Guardiola P, Anderson JE, Bandini G, et al: Allogeneic stem cell transplantation for
434. Santana-Davila R, Tefferi A, Holtan SG, et al: Primary myelofibrosis is the most fre- agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplan-
quent myeloproliferative neoplasm associated with del(5q): Clinicopathologic compar- tation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto Midollo
ison of del(5q)-positive and -negative cases. Leuk Res 32:1927, 2008. Osseo, and Fred Hutchinson Cancer Center Collaborative Study. Blood 93:2831, 1999.
435. Tefferi A, Lasho TL, Mesa RA, et al: Lenalidomide therapy in del(5)(q31)-associated 467. Deeg HJ, Appelbaum FR: Stem-cell transplantation for myelofibrosis. N Engl J Med
myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 21:1827, 334:775, 2001.
2007. 468. McCarty JM: Transplant strategies for idiopathic myelofibrosis. Semin Hematol
436. Cervantes F, Mesa R, Barosi G: New and old treatment modalities in primary myelofi- 41(Suppl 3):23, 2004.
brosis. Cancer J 13:377, 2007. 469. Mittal P, Saliba RM, Giralt SA, et al: Allogeneic transplantation: A therapeutic option for
437. Begna KH, Pardanani A, Mesa R, et al: Long-term outcome of pomalidomide therapy myelofibrosis, chronic myelomonocytic leukemia, and Philadelphia-negative BCR-ABL-
in myelofibrosis. Am J Hematol 87:66, 2012. negative chronic myelogenous leukemia. Bone Marrow Transplant 33:1005, 2004.

Kaushansky_chapter 86_p1319-1340.indd 1338 9/18/15 10:24 AM